New muramyl dipeptide (MDP) mimics without the carbohydrate moiety as potential adjuvant candidates for a therapeutic hepatitis B vaccine (HBV)

A series of new muramyl dipeptide (MDP) mimics were designed and synthesized via a solid-phase synthetic route. Their adjuvant activities were evaluated ex vivo for investigation of the synergism of the S(28–39) peptide, which is an MHC class I binding epitope of recombinant hepatitis B surface anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Nan, Ma, Yao, Zhang, Shengmei, Fang, Xin, Liang, Zhenglun, Liu, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2011
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126364/
https://www.ncbi.nlm.nih.gov/pubmed/21683593
http://dx.doi.org/10.1016/j.bmcl.2011.05.056
Descripción
Sumario:A series of new muramyl dipeptide (MDP) mimics were designed and synthesized via a solid-phase synthetic route. Their adjuvant activities were evaluated ex vivo for investigation of the synergism of the S(28–39) peptide, which is an MHC class I binding epitope of recombinant hepatitis B surface antigen (HBsAg) for both humans and mice. Several compounds without the carbohydrate moiety exerted better adjuvanticity than the MDP-C that has been reported by our laboratory previously. A primary screening test revealed that compounds 6, 14 and 16 exhibited stronger adjuvanticity compared with other MDP mimics.

Ejemplares similares